Guangdong Launches Province‑Wide Survey on “Three Entry” Channels for Centralized Drug Procurement – Questionnaire Open to Primary, Private and Retail Healthcare Outlets Until 30 Sep 2026

Leave a reply

Guangzhou, China – 04 Sep 2026 – The Guangdong Provincial Drug Trading Center announced a special province‑wide survey targeting all medical institutions participating in the “Three Entry” (三进) channels for centrally procured drugs — grassroots public healthcare providers, medical‑insurance‑designated private institutions, and designated retail pharmacies — to gather data on procurement status, demand forecasts, supplier relationships, and financial‑service needs ahead of the program’s full rollout.

Policy Milestone

ItemDetail
Issuing AuthorityGuangdong Provincial Drug Trading Center
Policy BasisNotice of the Guangdong Provincial Healthcare Security Administration on Promoting the Entry of Centrally Procured Drugs into Grassroots Medical Institutions, Private Medical Institutions and Retail Pharmacies (Yue Yi Bao Han [2025] No. 208)
Initiative“Three Entry” (三进) program — bringing volume‑based procurement (VBP) drugs to grassroots, private and retail channels
Notice Date4 Sep 2026
Submission Deadline30 Sep 2026
Filing MethodOnline questionnaire via QR code in the announcement — completed by the institution head or procurement lead
Support ChannelsHotline 020‑38302291; WeChat 19102021272 (weekdays 8:30–12:00, 14:00–17:30)

Survey Scope & Coverage

  • Public Grassroots Institutions: Township health centers, eligible community health service centers/stations, village clinics, and comparable primary‑care providers legally established and in normal operation within Guangdong.
  • Private Medical Institutions: Facilities designated under the medical‑insurance system.
  • Retail Pharmacies: Medical‑insurance‑designated drugstores, including both standalone and chain pharmacies.
  • Data Collected: Current procurement practices, procurement demand forecasts, existing procurement relationships, and financial‑service needs across all three channels.

Participation & Data Use

  • Filing Obligation: Institutions are asked to complete the Guangdong Province Centralized Drug Procurement “Three Entry” Project Questionnaire truthfully and accurately, reflecting actual operating conditions.
  • Purpose Limitation: Submitted information will be used only to optimize the provincial platform’s implementation plan for the “Three Entry” program, improve the procurement and supply‑chain service system, and deliver precision matchmaking services between channels and suppliers.
  • Deadline Discipline: The questionnaire closes on 30 Sep 2026; no extensions were mentioned in the notice.

Market Impact & Outlook

  • Extending VBP Beyond Public Hospitals: The “Three Entry” program pushes centrally procured, price‑compressed drugs down into primary care, private clinics, and retail pharmacies — significantly widening the reachable market for winning bidders in national and Guangdong provincial procurement rounds.
  • Data‑Driven Rollout: By first mapping demand forecasts and supply relationships channel‑by‑channel, Guangdong is signaling a precision‑implementation approach rather than a blanket mandate — survey results will likely shape distribution rules, platform workflows, and possibly channel‑specific financing support.
  • Strategic Signal for Suppliers and Distributors: Pharmaceutical manufacturers and distributors should treat the 30 Sep deadline as an early‑warning indicator: institutions that participate will be better positioned in subsequent matchmaking, and the survey footprint previews where VBP drug flow will be steered next.
  • Retail Channel Watch: Inclusion of chain and standalone pharmacies aligns with the national healthcare‑security agenda of routing VBP savings to outpatient and OTC‑adjacent settings — a structural shift for retail drug pricing in China’s largest provincial pharmaceutical market.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the implementation timeline, survey outcomes, and channel‑expansion plans of Guangdong’s “Three Entry” program for centrally procured drugs. Actual results may differ due to risks including participation rates, subsequent policy directives from provincial healthcare‑security authorities, supply‑chain capacity, and platform execution.-China Health Reform Pulse

Policy Source: https://www.gdmede.com.cn/announcement/announcement/detail?id=2096765545348075520

Yunnan Discloses Application Information for Normalized Listing of Medical Consumables – Batch 20260907 Opens Public Inquiry Ahead of Review

Leave a reply

Kunming, China – 07 Sep 2026 – The Yunnan Provincial Government Procurement and Transfer Center announced that application intake for the normalized online listing (挂网) of medical consumables (Batch 20260907) has been completed, and the submitted application information is now publicly disclosed for all participating enterprises on the Yunnan Provincial Drug Centralized Procurement Platform.

Procurement Milestone

ItemDetail
Issuing AuthorityYunnan Provincial Government Procurement and Transfer Center
Notice TypeApplication information disclosure (not a review‑result announcement)
ProgramNormalized online listing of medical consumables
Batch20260907
Disclosure Date7 Sep 2026
Access Route 1Yunnan Provincial Drug Centralized Procurement Platform → Procurement Subsystem (ggfw.ynylbz.cn) → Consumables Tender Management → Consumables Application Management → Product Public Inquiry
Access Route 2Direct link to the Batch 20260907 information disclosure
Next StepsAwait review‑result announcement; objections may be filed with supporting materials during the subsequent publicity period

Disclosure Details & Compliance Notes

  • Scope: The disclosure covers application information submitted by enterprises for the batch — i.e., products declared for listing on the provincial procurement platform, the gateway for selling medical consumables to public healthcare institutions in Yunnan.
  • Status Clarification: The Center explicitly stated that this publication is not a review‑result announcement; listing eligibility has not yet been determined.
  • No Action Required: Declaring enterprises need not submit any materials at this stage.
  • Objection Procedure: Once the review results are officially publicized, enterprises with objections may submit materials in accordance with the requirements of subsequent announcements during the publicity period.

Market Impact & Outlook

  • Routine but Critical Access Channel: Normalized listing (常态化挂网) is Yunnan’s ongoing mechanism for qualifying medical consumables on its centralized procurement platform; inclusion is effectively a prerequisite for hospital‑channel distribution in the province.
  • Transparency Signal: Publishing application‑level information before review outcomes — with a defined objection window — aligns with China’s broader push for open, rules‑based provincial procurement governance, allowing competitors and stakeholders to verify declared products early.
  • Watch Item for Suppliers: Device manufacturers and distributors should monitor the platform for the forthcoming review‑result publicity and calendar the objection window, as missed filings can delay or foreclose listing for this batch.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the review timeline, listing outcomes, and publicity procedures for Yunnan’s normalized medical consumables listing program (Batch 20260907). Actual results may differ due to risks including review determinations, objection filings, and subsequent policy or platform announcements.-China Health Reform Pulse

Policy Source: http://www.ynyyzb.com.cn/detail.html?infoId=27818&CatalogId=3

Shenzhen Launches Three‑Year AI Action Plan Targeting ¥300 Billion Core Industry by 2028 – 23 Key Tasks to Fuse AI with Research, Industry, Consumption and City Governance

Leave a reply

Shenzhen, China – 09 Sep 2026 – The Shenzhen Municipal People’s Government has officially released the “Shenzhen Action Plan for Promoting the Development of Artificial Intelligence and Applications (2026–2028)”, a three‑year blueprint targeting an AI core industry scale exceeding ¥300 billion (≈ US$42 billion), more than 3,000 AI enterprises, and an adoption rate above 90% for next‑generation smart terminals and AI agents by 2028, as the city accelerates its bid to become an “AI Pioneer City.”

Policy Snapshot

ItemDetail
Issuing AuthorityShenzhen Municipal People’s Government
PolicyShenzhen Action Plan for Promoting the Development of AI and Applications (2026–2028)
Time Horizon2026–2028
Core Industry TargetAI core industry scale exceeding ¥300 billion by 2028
Enterprise TargetMore than 3,000 AI companies
Adoption Target>90% penetration of next‑generation smart terminals and AI agents
Task Framework23 key tasks across six priority areas
Strategic GoalBuild Shenzhen into an “AI Pioneer City”

Six Priority Areas

  • Scientific Research: Shenzhen will build a “model–data–experiment” trinity technology system for scientific discovery, developing AI‑for‑Science foundation models on innovation platforms including Guangming Science City and Xili Lake International Science & Education City, and accelerating AI applications in biopharmaceuticals, high‑performance materials, and quantum technology.
  • Industrial Empowerment: AI will be embedded across the full advanced‑manufacturing value chain, with a push for industrial AI agents. The plan also drives AI convergence with professional services — finance, software, human resources, law, and accounting — expanding scenarios such as intelligent risk control, AI‑powered investment research, and AI coding.
  • AI‑Native Consumption: The city will foster “AI‑native” consumption, supporting AI phones, AI PCs, AI glasses, and humanoid robots, and exploring new formats such as digital avatars and AI emotional companionship. In culture and tourism, it backs intelligent NPCs, dynamic storylines, and AI comic dramas; in transport and logistics, it will expand last‑mile delivery by autonomous vehicles and drones across communities, business districts, and campuses.
  • People’s Livelihood: AI will empower employment, education, healthcare, elderly care, childcare, and housing. Shenzhen will continue to optimize its “Shen Xiaowei” health agent — offering smart triage, pre‑consultation intake, and medical report interpretation — and explore embodied‑intelligence devices for elder companionship and childcare supervision.
  • Urban Governance: Deep AI integration into city governance is listed among the six priority areas; specific measures were not detailed in the release.
  • Global Cooperation: Leveraging the Qianhai and Hetao platforms, Shenzhen will deepen international collaboration and refine the “Hong Kong R&D + Shenzhen Commercialization” model. Seizing the opportunity of the 33rd APEC Economic Leaders’ Informal Meeting, the city will showcase its AI solutions and push the “China AI stack” to go global, prioritizing Latin America, Southeast Asia, and Central Asia.

Foundation & Support Measures

  • Compute Infrastructure: Accelerate construction of flagship projects including Pengcheng Cloud Brain III.
  • Seven Pillars: Strengthen foundational capabilities in computing power, models, data, scenarios, talent, research platforms, and industrial funds.
  • Commercialization Pipeline: Move AI innovations from the laboratory to industry and urban applications at speed.

Market Impact & Outlook

  • National AI Race: The plan positions Shenzhen among China’s most aggressive municipal AI strategies, pairing a hard ¥300 billion core‑industry target with a 90% adoption benchmark that emphasizes real‑world deployment over pure research output.
  • Hardware Ecosystem Edge: Shenzhen’s consumer‑electronics supply chain — spanning AI phones, AI PCs, smart glasses, and humanoid robotics — gives it a structural advantage in monetizing the next wave of intelligent terminals.
  • Cross‑Border Innovation Model: The “Hong Kong R&D + Shenzhen Commercialization” pipeline, anchored by Qianhai and Hetao, offers a differentiated route for basic‑research translation under the Greater Bay Area framework.
  • Export Ambition: Targeting Latin America, Southeast Asia, and Central Asia, the plan signals a shift from exporting AI hardware to exporting full‑stack AI systems and governance solutions, with the APEC summit as a showcase moment.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding policy implementation timelines, industry scale targets, adoption rates, and commercialization expectations under Shenzhen’s AI Action Plan (2026–2028). Actual outcomes may differ due to risks including execution pace, technology maturation, funding availability, and the evolving global AI regulatory and competitive landscape.-China Health Reform Pulse

Policy Source: https://www.gd.gov.cn/zwgk/zcjd/snzcsd/content/post_4951847.html